

	p. 16 line 32
more than "1 billion"	p. 12 line 12
"injecting" the administered cells "diagonally through muscle fibers"	
	p. 12 lines 31-32
location "between laminae IV and V of the spinal cord"	p. 12 lines 37-38
"large chondroitin-6-sulfate"	p. 13 line 29, page 14 lines 1-3; lines 17-18
"insulin"	p. 13 line 21
"1 to 10 billion progeny myoblast"	p. 17 line 26

Applicant is a pioneer in the field of cell therapy using myoblasts. Applicant has discovered several methodological features that, to a layman may seem uninteresting or even trivial, such as using a large minimum number of cells to obtain success, use of allogenic cells (from the same patient), mechanical probing of the cells before sampling, and transverse injection into a recipient muscle. However, to a skilled artisan these factors are not obvious, yet one or more of them are absolutely crucial to success of the claimed method and cannot be dismissed. Applicant discovered the need for a minimum number of cells due to scavenging actions of the body, and this concept applies equally well to the claimed methods. Applicant has generated data that shows the extreme effect of mechanical probing, which most workers overlook. Likewise, applicant obtained data that shows the advantageous effect of transverse (compared with other types of) injection of cells into recipient muscle tissue. Yet another discovery that potentiates the claimed

method is the use of large chondroitin sulfate and also insulin. These features, alone, and especially in various combinations were not appreciated by artisans.

The invention is not a new peptide or protein but rather new methods for bringing together genes and expressing them within cells that can be placed where needed. New claims now are presented that recite the important methodological features of this method invention.

Reconsideration and allowance are requested.

The Commissioner is hereby authorized to charge for any excess claim fee, excess independent claims fee and surcharge for late filing to the undersigned's Deposit Account No. 08-1641. In the event any variance exists between the amount authorized and the Patent Office fees, please charge or credit any difference to the undersigned's Deposit Account No. 08-1641.

Respectfully submitted,

Date November 8, 2001

By Marvin Motsenbocker
Marvin Motsenbocker
Attorney for Applicant
Registration No. 36,614

Customer I.D. No. 26633
Heller Ehrman White & McAuliffe
1666 K Street, N.W., Suite 300
Washington, D.C. 20006
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

MARKED UP COPY OF SPECIFICATION

Page 1, following the title, please insert the following:

--This application is a continuation of Application No. 09/132,321 filed August 11, 1998, which is based on Provisional Application No. 60/055,199 filed August 11, 1997.--

0986344-110801
FOOT " 11298650